There are currently 80 active clinical trials seeking participants for Hepatocellular Carcinoma research studies. The states with the highest number of trials for Hepatocellular Carcinoma participants are California, Guangdong, Texas and New York.
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
NCT06184152
Recruiting
The study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: University of Michigan, Ann Arbor, Michigan +1 locations
Conditions: HCC, Hepatocellular Carcinoma
Register for Updates
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
NCT03916627
Recruiting
This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe and what side effects they cause; and other details about how they function in the body. One of the treatments that will be combined cemiplimab is another experimental drug called fianlimab. In this form, cemiplimab and fianlimab will each individually be called "study d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
NCT05176483
Recruiting
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors. In the Expansion Stage, the safety and efficacy of XL092 as monotherapy and in combination therapy will be further evaluated in t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2024
Locations: Exelixis Clinical Site #67, Phoenix, Arizona +121 locations
Conditions: Renal Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer, Urothelial Carcinoma, Solid Tumor, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
NCT05143619
Recruiting
This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "Teaching the Teachers" involves teaching the guidelines to experts who later teach the same guidelines to other radiologists, trainees, and physicians to assume the teacher's role and disseminate the guidelines and so on.
Gender:
ALL
Ages:
All
Trial Updated:
10/15/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hepatocellular Carcinoma
Register for Updates
Targeted Navigation in Hepatocellular Carcinoma (HCC)
NCT06260943
Recruiting
The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients. The investigators would like to know whether there are needs that patients have or are aware of, especially those needs that the investigators have not been able to address. The investigators aim to develop a program that helps participants and participant's families to navigate the process of being diagnosed with li... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: University of Miami, Miami, Florida
Conditions: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatobiliary Cancer
Register for Updates
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
NCT04374877
Recruiting
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: City of Hope, Duarte, California +20 locations
Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Arizona Health Research, Chandler, Arizona +71 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
NCT06007846
Recruiting
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Inova Schar Cancer Institute, Fairfax, Virginia +1 locations
Conditions: Hepatocellular Carcinoma, Cirrhosis
Register for Updates
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017
Recruiting
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical start... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: University of Southern California, Los Angeles, California +7 locations
Conditions: Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Register for Updates
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
NCT04857684
Recruiting
This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma. This study involves the following study interventions: * Atezolizumab * Bevacizumab * Stereotactic Beam Radiation Therapy (SBRT) * Surgery
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Register for Updates
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
NCT06265285
Recruiting
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Esophageal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Locally Advanced Urothelial Carcinoma, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Cutaneous Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
NCT06526338
Recruiting
The purpose of this study is to evaluate the safety and efficacy of a single injection of IP-001 as adjuvant therapy after local ablation or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Hepatocellular Carcinoma
Register for Updates